Aclaris Therapeutics (ACRS) Stock Analysis & AI Equity Report
Aclaris Therapeutics (ACRS) overview
Aclaris Therapeutics (ACRS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 7.8m and operating profit of USD -76.4m; the year-end share price was 3.01 USD and market capitalisation was USD 363m. Aclaris Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Aclaris Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Aclaris Therapeutics
Aclaris Therapeutics is a clinical-stage biopharmaceutical company discovering and developing small and large molecule product candidates for immuno-inflammatory diseases. Its programs include monoclonal and bispecific antibodies targeting inflammatory pathways and small molecule kinase inhibitors developed using its KINect platform. The company seeks third-party partners to further develop candidates, obtain marketing approval and commercialize products.
Generate the Aclaris Therapeutics report
Aclaris Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Aclaris Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Aclaris Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.